

JosÃ© R Blanco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4439237/publications.pdf>

Version: 2024-02-01

114
papers

3,004
citations

159358

30
h-index

205818

48
g-index

127
all docs

127
docs citations

127
times ranked

3915
citing authors

#	ARTICLE	IF	CITATIONS
1	Executive summary of the consensus document of the HIV quality of care indicators. GESIDA updated. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2022, 40, 35-38.	0.3	0
2	Mind the polypharmacy in people living with HIV. A new challenge for the fourth 90. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022, 40, 5-6.	0.2	0
3	Executive summary of the consensus document of the HIV quality of care indicators. GESIDA updated. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022, 40, 35-38.	0.2	0
4	Elevated levels of serum CDCP1 in individuals recovering from severe COVID-19 disease. <i>Aging</i> , 2022, 14, 1597-1610.	1.4	2
5	Temporal Trends and Geographic Variability in the Prescription of Antiretroviral Treatments in People Living with HIV in Spain, 2004â€“2020. <i>Journal of Clinical Medicine</i> , 2022, 11, 1896.	1.0	3
6	DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). <i>Viruses</i> , 2022, 14, 524.	1.5	7
7	Senotherapeutics in Cancer and HIV. <i>Cells</i> , 2022, 11, 1222.	1.8	7
8	Epidemiological, Clinical, and Microbiological Characteristics in a Large Series of Patients Affected by Dermacentor-Borne-Necrosis-Erythema-Lymphadenopathy from a Unique Centre from Spain. <i>Pathogens</i> , 2022, 11, 528.	1.2	6
9	The circadian rhythm of viruses and its implications on susceptibility to infection. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1109-1117.	2.0	3
10	Impact of HIV infection on aging and immune status. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 719-731.	2.0	10
11	Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25732.	1.2	14
12	Redefining therapeutic success in HIV patients: an expert view. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2501-2518.	1.3	15
13	Pulmonary long-term consequences of COVID-19 infections after hospital discharge. <i>Clinical Microbiology and Infection</i> , 2021, 27, 892-896.	2.8	85
14	COVIDâ€19 in hospitalized HIVâ€positive and HIVâ€negative patients: A matched study. <i>HIV Medicine</i> , 2021, 22, 867-876.	1.0	21
15	Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model. <i>Cancers</i> , 2021, 13, 4935.	1.7	9
16	IdentificaciÃ³n de creencias y actitudes relacionadas con la desprescripciÃ³n en pacientes VIH+ de edad avanzada: Proyecto ICARD. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 18-27.	0.5	5
17	How well are we performing the initial assessment of HIVâ€positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020, 21, 128-134.	1.0	0
18	Retinolâ€binding protein 4 (RBP4), a potential biomarker of frailty in HIVâ€infected people on stable antiretroviral therapy. <i>HIV Medicine</i> , 2020, 21, 358-364.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Deprescribing of non-antiretroviral therapy in HIV-infected patients. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 305-318.	0.8	19
20	Digital 3-Dimensional Virtual Models in Colorectal Cancer and Its Application in Surgical Practice. <i>Surgical Innovation</i> , 2020, 27, 246-247.	0.4	2
21	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , 2020, 7, e565-e573.	2.1	42
22	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1294-1300.	1.3	12
23	Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2). <i>PLoS ONE</i> , 2020, 15, e0226724.	1.1	2
24	Implications of maraviroc and/or rapamycin in a mouse model of fragility. <i>Aging</i> , 2020, 12, 8565-8582.	1.4	5
25	Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study). <i>Clinical Infectious Diseases</i> , 2019, 68, 120-130.	2.9	31
26	Gender differences for frailty in HIV-infected patients on stable antiretroviral therapy and with an undetectable viral load. <i>PLoS ONE</i> , 2019, 14, e0215764.	1.1	30
27	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrologia</i> , 2019, 39, 497-505.	0.2	5
28	Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1693-1700.	1.3	19
29	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2019, 37, 195-202.	0.3	9
30	Prosthetic Valve <i>Candida</i> spp. Endocarditis: New Insights Into Long-term Prognosisâ€”The ESCAPE Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 825-832.	2.9	40
31	Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. <i>Translational Research</i> , 2018, 196, 17-30.	2.2	12
32	Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial. <i>Clinical Microbiology and Infection</i> , 2018, 24, 900-907.	2.8	20
33	Barriers to health care services for migrants living with HIV in Spain. <i>European Journal of Public Health</i> , 2018, 28, 451-457.	0.1	23
34	Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: a qualitative approach. <i>BMC Women's Health</i> , 2018, 18, 24.	0.8	3
35	Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2731-2740.	1.2	65
36	The challenge of aging and pharmacotherapeutic complexity in the HIV + patient. <i>Farmacia Hospitalaria</i> , 2018, 42, 120-127.	0.6	10

#	ARTICLE	IF	CITATIONS
37	Maraviroc Ameliorates the Increased Adipose Tissue Macrophage Recruitment Induced by a High-Fat Diet in a Mouse Model of Obesity. <i>Antiviral Therapy</i> , 2017, 22, 163-168.	0.6	11
38	Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2017, 22, 21-29.	0.6	4
39	Quality indicators: A tool to improve efficiency. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 65-66.	0.3	1
40	Quality indicators: A tool to improve efficiency. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 65-66.	0.2	0
41	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 311-318.	0.9	12
42	Reproductive history before and after HIV diagnosis. <i>Medicine (United States)</i> , 2017, 96, e5991.	0.4	9
43	IL7RA polymorphisms are not associated with AIDS progression. <i>European Journal of Clinical Investigation</i> , 2017, 47, 719-727.	1.7	3
44	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. <i>Clinical Infectious Diseases</i> , 2017, 64, 1191-1197.	2.9	30
45	Aging in HIV-Infected Subjects: A New Scenario and a New View. <i>BioMed Research International</i> , 2017, 1-9.	0.9	56
46	Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM. <i>PLoS ONE</i> , 2017, 12, e0188851.	1.1	15
47	Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men. <i>Aids</i> , 2016, 30, 37-44.	1.0	46
48	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	1.7	60
49	The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 993-996.	2.0	3
50	High prevalence of asymptomatic carriers of <i>Tropheryma whipplei</i> in different populations from the North of Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 340-345.	0.3	13
51	HCV genotype 3: a wolf in sheep's clothing. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 149-152.	2.0	5
52	Off-label use of maraviroc in clinical practice. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 5-8.	2.0	4
53	Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. <i>HIV Medicine</i> , 2015, 16, 628-634.	1.0	14
54	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1-Infected Patients Treated With Combined Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 21-29.	0.9	23

#	ARTICLE	IF	CITATIONS
55	The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 893-897.	0.5	4
56	Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naïve patients aged 50 years or older in Spain: The TRIP study. <i>HIV Clinical Trials</i> , 2015, 16, 43-48.	2.0	4
57	Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. <i>Antiviral Research</i> , 2015, 120, 79-84.	1.9	16
58	Left-sided infective endocarditis in patients with liver cirrhosis. <i>Journal of Infection</i> , 2015, 71, 627-641.	1.7	14
59	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.3	10
60	Relevant Gender Differences in Epidemiological Profile, Exposure to First Antiretroviral Regimen and Survival in the Spanish Aids Research Network Cohort. <i>Antiviral Therapy</i> , 2014, 19, 375-385.	0.6	9
61	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004-2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226.	1.1	19
62	Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19544.	1.2	6
63	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014, 32, 447-458.	0.3	14
64	Reproductive desire in women with HIV infection in Spain, associated factors and motivations: a mixed-method study. <i>BMC Pregnancy and Childbirth</i> , 2014, 14, 194.	0.9	17
65	Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1903-1910.	1.3	61
66	Gut microbiota: so much to explore!. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 759-761.	2.0	0
67	What Drives the Number of High-Risk Human Papillomavirus Types in the Anal Canal in HIV-Positive Men Who Have Sex With Men?. <i>Journal of Infectious Diseases</i> , 2013, 207, 1235-1241.	1.9	33
68	Anal Human Papillomavirus Genotype Distribution in HIV-Infected Men Who Have Sex with Men by Geographical Origin, Age, and Cytological Status in a Spanish Cohort. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3512-3520.	1.8	46
69	Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naïve Subjects Aged 50 Years or Older in Spain: The TRIP Study. <i>HIV Clinical Trials</i> , 2013, 14, 204-215.	2.0	3
70	Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: a pilot study. <i>Journal of the International AIDS Society</i> , 2013, 16, 18609.	1.2	7
71	Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naïve Subjects Aged 50 Years or Older in Spain: The TRIP Study. <i>HIV Clinical Trials</i> , 2013, 14, 204-215.	2.0	1
72	Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model. <i>PLoS ONE</i> , 2013, 8, e53992.	1.1	75

#	ARTICLE	IF	CITATIONS
73	Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care. <i>Antiviral Therapy</i> , 2012, 17, 1-8.	0.6	43
74	Could CCR5 be a potential target against infections?. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 411-414.	2.0	1
75	Definition of Advanced Age in HIV Infection: Looking for an Age Cut-Off. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1000-1006.	0.5	56
76	Q fever endocarditis associated with a cardiovascular implantable electronic device. <i>Clinical Microbiology and Infection</i> , 2012, 18, E482-E484.	2.8	12
77	Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells. <i>Journal of Infection and Chemotherapy</i> , 2012, 18, 485-493.	0.8	4
78	Septic shock in a patient infected with <i>Rickettsia sibirica mongolitimonae</i> , Spain. <i>Clinical Microbiology and Infection</i> , 2012, 18, E283-E285.	2.8	27
79	Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naïve HIV-infected individuals (CoRIS). <i>Antiviral Research</i> , 2011, 91, 150-153.	1.9	37
80	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 358-362.	1.3	20
81	Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes. <i>Current HIV Research</i> , 2011, 9, 174-179.	0.2	23
82	Hot Immunological Topics in HIV Infection. <i>Journal of AIDS & Clinical Research</i> , 2011, 02, .	0.5	9
83	Palpebral ptosis related to antiretroviral therapy: report of two new cases and review of the literature. <i>HIV and AIDS Review</i> , 2010, 9, 109-111.	0.1	1
84	HIV infection and aging. <i>AIDS Reviews</i> , 2010, 12, 218-30.	0.5	38
85	<i>Bartonella rochalimae</i> and Other <i>Bartonella</i> spp. in Fleas, Chile. <i>Emerging Infectious Diseases</i> , 2009, 15, 1150-1152.	2.0	39
86	Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART. <i>Current HIV Research</i> , 2009, 7, 612-619.	0.2	26
87	Patients Characteristics and Clinical Implications of Suboptimal CD4 T-Cell Gains After 1 Year of Successful Antiretroviral Therapy. <i>Current HIV Research</i> , 2008, 6, 100-107.	0.2	66
88	Q fever in Logroño: an attack scenario. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007, 25, 199-203.	0.3	5
89	Detection of <i>Rickettsia africae</i> in <i>Rhipicephalus (Boophilus) decoloratus</i> Ticks from the Republic of Botswana, South Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 376-377.	0.6	30
90	Symptomatic nosocomial urinary tract infection in very elderly patients. <i>International Journal of Infectious Diseases</i> , 2006, 10, 181-183.	1.5	2

#	ARTICLE	IF	CITATIONS
91	Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort. PLoS ONE, 2006, 1, e89.	1.1	42
92	A Century of Rickettsiology: Emerging, Reemerging Rickettsioses, Clinical, Epidemiologic, and Molecular Diagnostic Aspects and Emerging Veterinary Rickettsioses: An Overview. Annals of the New York Academy of Sciences, 2006, 1078, 1-14.	1.8	16
93	Rickettsiosis in Europe. Annals of the New York Academy of Sciences, 2006, 1078, 26-33.	1.8	36
94	Rickettsia slovaca Infection: DEBONEL/TIBOLA. Annals of the New York Academy of Sciences, 2006, 1078, 206-214.	1.8	71
95	Prevalence of Rickettsia felis-like and Bartonella Spp. in Ctenocephalides felis and Ctenocephalides canis from La Rioja (Northern Spain). Annals of the New York Academy of Sciences, 2006, 1078, 270-274.	1.8	31
96	Prevalence of Rickettsia felis in Ctenocephalides felis and Ctenocephalides canis from Uruguay. Annals of the New York Academy of Sciences, 2006, 1078, 305-308.	1.8	33
97	Prevalence of Spotted Fever Group Rickettsia Species Detected in Ticks in La Rioja, Spain. Annals of the New York Academy of Sciences, 2006, 1078, 320-323.	1.8	30
98	Evaluation of IgG Antibody Response against Rickettsia conorii and Rickettsia slovaca in Patients with DEBONEL/TIBOLA. Annals of the New York Academy of Sciences, 2006, 1078, 570-572.	1.8	7
99	Cluster of Cases of Human Rickettsia felis Infection from Southern Europe (Spain) Diagnosed by PCR. Journal of Clinical Microbiology, 2006, 44, 2669-2671.	1.8	78
100	Effect of Antibiotic Treatment in Patients with DEBONEL/TIBOLA. Annals of the New York Academy of Sciences, 2005, 1063, 257-258.	1.8	11
101	Detection of a Non-Pathogenic Variant of Anaplasma phagocytophilum in Ixodes ricinus from La Rioja, Spain. Annals of the New York Academy of Sciences, 2005, 1063, 333-336.	1.8	16
102	DEBONEL/TIBOLA: Is Rickettsia slovaca the Only Etiological Agent?. Annals of the New York Academy of Sciences, 2005, 1063, 346-348.	1.8	21
103	Low Risk of Developing Human Rickettsia aeschlimannii Infection in the North of Spain. Annals of the New York Academy of Sciences, 2005, 1063, 349-351.	1.8	16
104	Dermacentor-borne necrosis erythema and lymphadenopathy: clinical and epidemiological features of a new tick-borne disease. Clinical Microbiology and Infection, 2004, 10, 327-331.	2.8	90
105	Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clinical Microbiology and Infection, 2004, 10, 1108-1132.	2.8	328
106	Infecci3n por Rickettsia africae. Tres casos confirmados por reacci3n en cadena de la polimerasa. Medicina Cl3nica, 2004, 122, 786-788.	0.3	14
107	Relapsing brucellosis in a patient infected with the human immunodeficiency virus (HIV). Clinical Microbiology and Infection, 2003, 9, 1259-1260.	2.8	12
108	Epidemiological and Clinical Differences among Rickettsia slovaca Rickettsiosis and Other Tick-Borne Diseases in Spain. Annals of the New York Academy of Sciences, 2003, 990, 355-356.	1.8	15

#	ARTICLE	IF	CITATIONS
109	Epidemiological and Clinical Differences among DEBONELÁCTIBOLA and Other Tickâ€Borne Diseases in Spain. <i>Annals of the New York Academy of Sciences</i> , 2003, 990, 391-392.	1.8	8
110	Human granulocytic ehrlichiosis in Europe. <i>Clinical Microbiology and Infection</i> , 2002, 8, 763-772.	2.8	190
111	Bloodstream Infections After Invasive Nonsurgical Cardiac Procedures. <i>Archives of Internal Medicine</i> , 2001, 161, 2110.	4.3	42
112	Presence of granulocytic ehrlichia in ticks and serological evidence of human infection in La Rioja, Spain. <i>Epidemiology and Infection</i> , 2001, 127, 353-358.	1.0	34
113	Efficacy of Cidofovir in the Treatment of Recalcitrant Molluscum Contagiosum in an AIDS Patient. <i>Acta Dermato-Venereologica</i> , 2000, 80, 315-316.	0.6	32
114	First Report of Human Granulocytic Ehrlichiosis from Southern Europe (Spain). <i>Emerging Infectious Diseases</i> , 2000, 6, 430-432.	2.0	54